Pancreatic Cancer Clinical Trials in Los Angeles

Showing 101-120 of 149 trials

Veliparib in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Pancreatic Cancer

NCT01908478

This is a Phase I Study of veliparib (ABT-888) in combination with Gemcitabine and Intensity Modulated Radiation Therapy in Patients with Locally Advanced, Unresectable Pancreatic Cancer. Primary Objectives: * Determine the maximum tolerable dose of veliparib in combination with gemcitabine and intensity modulated radiation therapy in patients with locally advanced pancreatic cancer. * Determine the safety and toxicity of the combination of veliparib with gemcitabine and radiation therapy in patients with locally advanced pancreatic cancer

Pancreatic Cancer

Cedars-Sinai Medical Center34 participantsStarted Oct 2013

Los Angeles, California, United States

COMPLETEDPhase 2< 1 mile

Vaccine Study for Surgically Resected Pancreatic Cancer

NCT00569387

To assess the response for subjects with pancreatic cancer that have undergone surgical resection and treatment with a vaccine given with chemotherapy and chemoradiation.

Pancreatic Cancer

NewLink Genetics Corporation73 participantsStarted Dec 2007

Scottsdale, Arizona, United States • Los Angeles, California, United States • Orange, California, United States +15 more locations

Veliparib in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Pancreatic Cancer

Vaccine Study for Surgically Resected Pancreatic Cancer

Pancreatic Cancer Trials in Other Cities

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors

OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.

Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery

Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma

Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting

Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers

Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer

Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma

A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer

High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery

Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer

Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer

Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer

Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer

A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

Other Conditions in Los Angeles